Company news

Brii Biosciences Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Next Day Disclosure Return

October 30, 2026

Next Day Disclosure Return

October 29, 2026

Next Day Disclosure Return

October 28, 2026

Next Day Disclosure Return

October 27, 2026

Next Day Disclosure Return

October 26, 2026

Next Day Disclosure Return

October 23, 2026

Next Day Disclosure Return

October 22, 2026

Next Day Disclosure Return

October 21, 2026

Next Day Disclosure Return

October 20, 2026

Next Day Disclosure Return

October 16, 2026

VOLUNTARY ANNOUNCEMENT Launch of BRiSC, an siRNA Therapeutics Discovery Platform

October 15, 2026

Next Day Disclosure Return

October 14, 2026

Next Day Disclosure Return

October 13, 2026

Next Day Disclosure Return

October 12, 2026

Next Day Disclosure Return

October 9, 2026

Grant of share options and restricted share units

October 8, 2026

Monthly return of equity issuer on movements in securities for the month ended 30 September 2026

October 7, 2026

Notification Letter and Request Form for Non-registered Shareholders

September 17, 2026

Notification Letter and Change Request Form for Registered Shareholders

September 17, 2026

2026 Interim Report

September 17, 2026

Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results

August 20, 2026

Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B

July 2, 2026

Brii Bio Presents Late-Breaking Data from Its Phase 2 ENSURE Study at EASL Congress 2026, Further Supporting the Potential Role of BRII-179 in Achieving Durable Immunological Control of HBV

May 27, 2026

Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026

April 26, 2026

Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results

March 19, 2026

Brii Biosciences and OpenBench Announce AI-Driven Collaboration for Proprietary Technology Platform

December 11, 2025

Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B

November 10, 2025

Brii Biosciences Announces Publication of Phase 2 ENSURE Study Results in Nature Medicine

November 7, 2025

Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results

August 21, 2025

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

July 3, 2025

Brii Bio Presents Late-Breaking Data from Its Ongoing Phase 2 ENSURE Study at EASL Congress 2025, Suggesting BRII-179's Role in Advancing Higher HBsAg Loss

May 7, 2025

Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

March 30, 2025

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

March 21, 2025

Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study

January 2, 2025

Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024

June 7, 2024

Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies

May 13, 2024

Brii Biosciences Announces Agreements To Acquire VBI Vaccines' IP Rights In BRII-179

March 5, 2024

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

February 13, 2024

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer

January 3, 2024

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B

September 6, 2023

Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

August 22, 2023

Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure

July 5, 2023

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

July 5, 2023

Brii Biosciences Announces Entry into Definitive Agreements from Sale of its Equity Interest in Qpex Biopharma and Acquiring Exclusive Global Rights for BRII-693

June 25, 2023

Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders

May 30, 2023

Brii Bio Publishes 2022 Environmental, Social and Governance Report

April 27, 2023

Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression

September 26, 2022

Calls

Decks

The 5 newest of 8 decks. Every deck is listed under its year.